BMS-241027

BMS-241027 (Epothilone D) is a small-molecule microtubule stabilizer that was developed by Bristol Myers Squibb for the treatment of Alzheimer's disease. It belongs to the epothilone class of compounds, which are known for their ability to bind to and stabilize microtubules, similar to taxanes. In the context of Alzheimer's disease and other tauopathies, the rationale for using BMS-241027 was that stabilizing microtubules could compensate for the loss of function of the tau protein, which normally stabilizes microtubules but becomes dysfunctional and forms aggregates in these diseases. By maintaining microtubule integrity, the drug aimed to preserve axonal transport and neuronal function. Clinical development reached Phase 1, where it was evaluated for safety, tolerability, and effects on cerebrospinal fluid biomarkers in patients with mild Alzheimer's disease, but the program was discontinued in 2013.

Other names

Epothilone D